BiotechTube
Tillotts Pharma

Tillotts Pharma

Rheinfelden, Switzerland· Est.
tillotts.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Tillotts Pharma is a commercial-stage, privately held specialty pharma company with a deep focus on gastroenterology. As part of the Zeria Group since 2010, it leverages a global partnership network to market its portfolio of small molecule therapeutics, primarily for inflammatory bowel disease (IBD). With over 400 employees, the company is in a growth phase, expanding its geographic reach through strategic partnerships, such as its recent deal for China.

GastroenterologyInflammatory Bowel Disease

Technology Platform

Specialized small molecule formulation and drug delivery for gastrointestinal diseases, with deep expertise in lifecycle management of GI therapeutics.

Opportunities

Significant growth potential exists in geographic expansion into large, underserved markets like China through strategic partnerships.
The rising global prevalence of IBD and other chronic GI disorders provides a expanding addressable patient population.
Opportunities also lie in lifecycle management of existing products and in-licensing of late-stage GI assets to broaden the portfolio.

Risk Factors

Revenue dependency on a narrow portfolio of products, primarily mesalazine, exposes the company to generic competition.
The highly competitive GI landscape, dominated by large pharma with novel biologics, creates pricing and market share pressure.
Strategic reliance on third-party distribution partners and the overarching control of parent company Zeria introduce operational and strategic risks.

Competitive Landscape

Tillotts competes in the crowded gastroenterology market, facing large pharmaceutical companies (e.g., AbbVie, Takeda, Johnson & Johnson) with extensive biologic portfolios for IBD, as well as other specialty pharma and generic manufacturers. Its competitive advantage is its pure-play GI focus, deep specialist relationships, and expertise in formulating and commercializing established small molecule therapies, often in niches or regions with less intense competition.

More companies in Small Molecule Drugs →More companies in Switzerland →